SK285766B6 - Farmaceutická kompozícia obsahujúca nukleotidový analóg a spôsob jej prípravy - Google Patents

Farmaceutická kompozícia obsahujúca nukleotidový analóg a spôsob jej prípravy Download PDF

Info

Publication number: SK285766B6
Authority: SK; Slovakia
Prior art keywords: pharmaceutical composition; dried; compound; drying; preparation
Prior art date: 1997-07-11

Application number

SK1836-99A

Other languages

English (en)

Slovak (sk)

Other versions

SK183699A3 (en

Inventor

Joanne Broadhead

Original Assignee

Astrazeneca Uk Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-07-11

Filing date

1998-06-29

Publication date

2007-07-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285766(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-06-29 Application filed by Astrazeneca Uk Ltd filed Critical Astrazeneca Uk Ltd

2000-07-11 Publication of SK183699A3 publication Critical patent/SK183699A3/sk

2007-07-06 Publication of SK285766B6 publication Critical patent/SK285766B6/sk

Links

239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 19
125000003729 nucleotide group Chemical group 0.000 title claims abstract description 13
238000000034 method Methods 0.000 title claims abstract description 12
238000002360 preparation method Methods 0.000 title claims abstract description 6
230000008569 process Effects 0.000 title claims abstract description 5
239000000654 additive Substances 0.000 claims abstract description 4
238000007496 glass forming Methods 0.000 claims abstract 2
239000000203 mixture Substances 0.000 claims description 24
150000001875 compounds Chemical class 0.000 claims description 22
150000003839 salts Chemical class 0.000 claims description 11
229930006000 Sucrose Natural products 0.000 claims description 8
239000005720 sucrose Substances 0.000 claims description 8
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
238000001035 drying Methods 0.000 claims description 6
239000002773 nucleotide Substances 0.000 claims description 6
238000011282 treatment Methods 0.000 claims description 5
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 4
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 4
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
239000000600 sorbitol Substances 0.000 claims description 3
208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
206010002383 Angina Pectoris Diseases 0.000 claims description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
229920002307 Dextran Polymers 0.000 claims description 2
238000007887 coronary angioplasty Methods 0.000 claims description 2
208000035475 disorder Diseases 0.000 claims description 2
238000007710 freezing Methods 0.000 claims description 2
230000008014 freezing Effects 0.000 claims description 2
238000002156 mixing Methods 0.000 claims description 2
238000001694 spray drying Methods 0.000 claims description 2
230000000996 additive effect Effects 0.000 claims 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 1
208000010110 spontaneous platelet aggregation Diseases 0.000 claims 1
125000000185 sucrose group Chemical group 0.000 claims 1
239000007921 spray Substances 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
238000004108 freeze drying Methods 0.000 description 9
-1 NR 6 R 7 Chemical group 0.000 description 8
239000012535 impurity Substances 0.000 description 8
GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 8
238000003860 storage Methods 0.000 description 7
230000001732 thrombotic effect Effects 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 6
239000002253 acid Substances 0.000 description 5
229910052736 halogen Inorganic materials 0.000 description 5
150000002367 halogens Chemical class 0.000 description 5
206010010904 Convulsion Diseases 0.000 description 4
239000000243 solution Substances 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
229910052801 chlorine Inorganic materials 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
229910052731 fluorine Inorganic materials 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
208000010125 myocardial infarction Diseases 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
230000010118 platelet activation Effects 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 2
206010002388 Angina unstable Diseases 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
208000018262 Peripheral vascular disease Diseases 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
208000007814 Unstable Angina Diseases 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
KVLRBRZHCOVMNX-IDTAVKCVSA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-[6-(2-methylsulfanylethylamino)-2-(3,3,3-trifluoropropylsulfanyl)purin-9-yl]oxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(NCCSC)=NC(SCCC(F)(F)F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O KVLRBRZHCOVMNX-IDTAVKCVSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000002296 eclampsia Diseases 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000011521 glass Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
208000014674 injury Diseases 0.000 description 2
201000004332 intermediate coronary syndrome Diseases 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
208000013223 septicemia Diseases 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
230000008733 trauma Effects 0.000 description 2
230000002792 vascular Effects 0.000 description 2
OVBICQMTCPFEBS-SATRDZAXSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound CC(O)=O.CC(O)=O.C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 OVBICQMTCPFEBS-SATRDZAXSA-N 0.000 description 1
XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 1
FDSYTWVNUJTPMA-UHFFFAOYSA-N 2-[3,9-bis(carboxymethyl)-3,6,9,15-tetrazabicyclo[9.3.1]pentadeca-1(15),11,13-trien-6-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC2=CC=CC1=N2 FDSYTWVNUJTPMA-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000037157 Azotemia Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
235000003880 Calendula Nutrition 0.000 description 1
240000001432 Calendula officinalis Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000019695 Migraine disease Diseases 0.000 description 1
208000014767 Myeloproliferative disease Diseases 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
208000031481 Pathologic Constriction Diseases 0.000 description 1
229920000388 Polyphosphate Polymers 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
208000005485 Thrombocytosis Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
208000012346 Venoocclusive disease Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
229960004676 antithrombotic agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000003073 embolic effect Effects 0.000 description 1
238000013171 endarterectomy Methods 0.000 description 1
238000002618 extracorporeal membrane oxygenation Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
108700032141 ganirelix Proteins 0.000 description 1
230000009477 glass transition Effects 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
150000002337 glycosamines Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
150000002443 hydroxylamines Chemical class 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
206010027599 migraine Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000002972 pentoses Chemical class 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000002616 plasmapheresis Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000001205 polyphosphate Substances 0.000 description 1
235000011176 polyphosphates Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
238000004321 preservation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
239000003352 sequestering agent Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000036262 stenosis Effects 0.000 description 1
208000037804 stenosis Diseases 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000003634 thrombocyte concentrate Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000012929 tonicity agent Substances 0.000 description 1
125000004417 unsaturated alkyl group Chemical group 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK1836-99A 1997-07-11 1998-06-29 Farmaceutická kompozícia obsahujúca nukleotidový analóg a spôsob jej prípravy SK285766B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9702680A SE9702680D0 (sv)	1997-07-11	1997-07-11	New formulation
PCT/SE1998/001287 WO1999002542A1 (en)	1997-07-11	1998-06-29	New formulation

Publications (2)

Publication Number	Publication Date
SK183699A3 SK183699A3 (en)	2000-07-11
SK285766B6 true SK285766B6 (sk)	2007-07-06

Family

ID=20407718

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1836-99A SK285766B6 (sk)	1997-07-11	1998-06-29	Farmaceutická kompozícia obsahujúca nukleotidový analóg a spôsob jej prípravy

Country Status (35)

Country	Link
US (1)	US6130208A (id)
EP (1)	EP1000079B1 (id)
JP (1)	JP4950380B2 (id)
KR (1)	KR100786654B1 (id)
CN (2)	CN1864696A (id)
AR (1)	AR013157A1 (id)
AT (1)	ATE340801T1 (id)
AU (1)	AU8362598A (id)
BR (1)	BR9810703A (id)
CA (1)	CA2295628C (id)
CY (1)	CY1105805T1 (id)
CZ (1)	CZ298110B6 (id)
DE (1)	DE69836023T2 (id)
DK (1)	DK1000079T3 (id)
EE (1)	EE04119B1 (id)
ES (1)	ES2273425T3 (id)
HU (1)	HU226489B1 (id)
ID (1)	ID24716A (id)
IL (2)	IL133868A0 (id)
IS (1)	IS2439B (id)
MY (1)	MY116421A (id)
NO (1)	NO329918B1 (id)
NZ (1)	NZ502073A (id)
PL (1)	PL192768B1 (id)
PT (1)	PT1000079E (id)
RU (1)	RU2216330C2 (id)
SA (1)	SA98190328B1 (id)
SE (1)	SE9702680D0 (id)
SI (1)	SI1000079T1 (id)
SK (1)	SK285766B6 (id)
TR (1)	TR200000006T2 (id)
TW (1)	TW585764B (id)
UA (1)	UA65576C2 (id)
WO (1)	WO1999002542A1 (id)
ZA (1)	ZA985669B (id)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4986281B2 (ja) *	2004-10-05	2012-07-25	旭化成ファーマ株式会社	補酵素の安定化方法およびその組成物
US9427448B2 (en)	2009-11-11	2016-08-30	The Medicines Company	Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20130303477A1 (en)	2008-05-13	2013-11-14	The Medicines Company	Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en)	2008-05-13	2009-11-19	The Medicines Company	Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en)	2008-05-13	2014-06-24	The Medicines Company	Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en)	2008-05-13	2012-06-07	Lisa Ruderman Chen	Maintenance of platelet inhibition during antiplatelet therapy
US9925265B2 (en)	2009-11-11	2018-03-27	Chiesi Farmaceutici S.P.A.	Methods of treating or preventing stent thrombosis
ES2470329T3 (es)	2009-08-28	2014-06-23	Daiichi Sankyo Company, Limited	Derivado del ácido 3-(biariloxi) priopi�nico
US10376532B2 (en)	2009-11-11	2019-08-13	Chiesi Farmaceutici, S.P.A.	Methods of treating, reducing the incidence of, and/or preventing ischemic events
MX2013006127A (es) *	2010-12-10	2013-09-26	Sigmapharm Lab Llc	Composiciones sumamente estables de analogos nucleotidicoas oralmente activos o profarmacos analogos nucleotidicos oralmente activos.
BR112013020377B1 (pt)	2011-02-09	2022-06-07	Chiesi Farmaceutici S.P.A.	Usos de um antagonista do receptor p2y12 reversível na fabricação de um medicamento útil para o tratamento da hipertensão pulmonar
US9700347B2 (en)	2011-08-17	2017-07-11	Samuel Shiber	Adaptive rotary catheter for opening obstructed bodily vessels
EA034550B1 (ru)	2013-03-09	2020-02-19	КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А.	Способы лечения, снижения частоты и/или профилактики ишемических событий
CN103772461A (zh) *	2014-01-06	2014-05-07	南京正科制药有限公司	一种坎格雷洛晶型ⅰ
BR112017014996A2 (pt)	2015-01-14	2018-03-20	Chiesi Farm Spa	formulações farmacêuticas e recipientes selados
EP3641784A1 (en)	2017-06-23	2020-04-29	Chiesi Farmaceutici S.p.A.	Method of preventing of systemic-to-pulmonary-artery shunt thrombosis
TWI857957B (zh)	2018-06-19	2024-10-11	德商Ｕｃｂ製藥有限公司	吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5637967B2 (id) *	1973-05-17	1981-09-03
JPS5874966A (ja) *	1981-10-28	1983-05-06	Mikuni Jukogyo Kk	高圧往復動機の軸封装置
JPS5874696A (ja) *	1981-10-30	1983-05-06	株式会社　ヤトロン	アデノシン三リン酸の安定化方法
AU659645B2 (en) *	1991-06-26	1995-05-25	Inhale Therapeutic Systems	Storage of materials
ES2129048T3 (es) *	1991-12-09	1999-06-01	Asahi Chemical Ind	Composicion estabilizada de hormona paratiroide.
ATE159950T1 (de) *	1993-02-10	1997-11-15	Astra Pharma Prod	N-alkyl-2-substituierte atp-analoge
PE36795A1 (es) *	1993-12-14	1995-11-06	Lilly Co Eli	Complejo de inclusion en solucion acuosa de compuestos de benzotiofeno con ciclodextrinas solubles en agua, formulaciones farmaceuticas y procedimiento de obtencion
DE4405426A1 (de) *	1994-02-21	1995-08-24	Boehringer Mannheim Gmbh	Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
AU707734B2 (en) *	1995-06-07	1999-07-15	Regents Of The University Of California, The	Stabilization of polynucleotide complexes
FR2740686B1 (fr) *	1995-11-03	1998-01-16	Sanofi Sa	Formulation pharmaceutique lyophilisee stable
SE9604795D0 (sv) *	1996-12-20	1996-12-20	Astra Pharma Prod	New pharmaceutical formulation

1997
- 1997-07-11 SE SE9702680A patent/SE9702680D0/xx unknown
1998
- 1998-06-19 TW TW087109890A patent/TW585764B/zh not_active IP Right Cessation
- 1998-06-29 PT PT98934017T patent/PT1000079E/pt unknown
- 1998-06-29 KR KR1020007000205A patent/KR100786654B1/ko not_active Expired - Lifetime
- 1998-06-29 SK SK1836-99A patent/SK285766B6/sk not_active IP Right Cessation
- 1998-06-29 CN CNA2006100092846A patent/CN1864696A/zh active Pending
- 1998-06-29 HU HU0002622A patent/HU226489B1/hu unknown
- 1998-06-29 ZA ZA985669A patent/ZA985669B/xx unknown
- 1998-06-29 ID IDW20000028A patent/ID24716A/id unknown
- 1998-06-29 RU RU2000103216/14A patent/RU2216330C2/ru active
- 1998-06-29 UA UA2000010491A patent/UA65576C2/uk unknown
- 1998-06-29 CA CA002295628A patent/CA2295628C/en not_active Expired - Lifetime
- 1998-06-29 DE DE69836023T patent/DE69836023T2/de not_active Expired - Lifetime
- 1998-06-29 JP JP2000502063A patent/JP4950380B2/ja not_active Expired - Lifetime
- 1998-06-29 US US09/125,165 patent/US6130208A/en not_active Expired - Lifetime
- 1998-06-29 CN CN98807089A patent/CN1263533A/zh active Pending
- 1998-06-29 NZ NZ502073A patent/NZ502073A/en not_active IP Right Cessation
- 1998-06-29 EE EEP200000022A patent/EE04119B1/xx unknown
- 1998-06-29 WO PCT/SE1998/001287 patent/WO1999002542A1/en active IP Right Grant
- 1998-06-29 AT AT98934017T patent/ATE340801T1/de active
- 1998-06-29 IL IL13386898A patent/IL133868A0/xx unknown
- 1998-06-29 SI SI9830865T patent/SI1000079T1/sl unknown
- 1998-06-29 TR TR2000/00006T patent/TR200000006T2/xx unknown
- 1998-06-29 CZ CZ20000083A patent/CZ298110B6/cs not_active IP Right Cessation
- 1998-06-29 ES ES98934017T patent/ES2273425T3/es not_active Expired - Lifetime
- 1998-06-29 PL PL337970A patent/PL192768B1/pl unknown
- 1998-06-29 EP EP98934017A patent/EP1000079B1/en not_active Expired - Lifetime
- 1998-06-29 DK DK98934017T patent/DK1000079T3/da active
- 1998-06-29 BR BR9810703-8A patent/BR9810703A/pt not_active Application Discontinuation
- 1998-06-29 AU AU83625/98A patent/AU8362598A/en not_active Abandoned
- 1998-06-30 AR ARP980103182A patent/AR013157A1/es not_active Application Discontinuation
- 1998-07-10 MY MYPI98003170A patent/MY116421A/en unknown
- 1998-07-21 SA SA98190328A patent/SA98190328B1/ar unknown
1999
- 1999-12-30 IS IS5331A patent/IS2439B/is unknown
2000
- 2000-01-03 IL IL133868A patent/IL133868A/en not_active IP Right Cessation
- 2000-01-10 NO NO20000123A patent/NO329918B1/no not_active IP Right Cessation
2006
- 2006-11-27 CY CY20061101705T patent/CY1105805T1/el unknown

Also Published As

Publication number	Publication date
AR013157A1 (es)	2000-12-13
CN1864696A (zh)	2006-11-22
HUP0002622A3 (en)	2002-04-29
EE200000022A (et)	2000-10-16
IS2439B (is)	2008-11-15
CZ298110B6 (cs)	2007-06-27
DE69836023D1 (de)	2006-11-09
KR100786654B1 (ko)	2007-12-21
UA65576C2 (uk)	2004-04-15
JP2001509512A (ja)	2001-07-24
CZ200083A3 (cs)	2000-06-14
US6130208A (en)	2000-10-10
IL133868A (en)	2010-05-17
NZ502073A (en)	2001-09-28
ZA985669B (en)	1999-01-11
HK1026429A1 (en)	2000-12-15
TR200000006T2 (tr)	2000-07-21
EP1000079B1 (en)	2006-09-27
CA2295628A1 (en)	1999-01-21
NO20000123L (no)	2000-03-03
WO1999002542A1 (en)	1999-01-21
CA2295628C (en)	2008-07-29
PL192768B1 (pl)	2006-12-29
DE69836023T2 (de)	2007-04-12
RU2216330C2 (ru)	2003-11-20
SK183699A3 (en)	2000-07-11
KR20010021647A (ko)	2001-03-15
PL337970A1 (en)	2000-09-11
BR9810703A (pt)	2000-08-08
IS5331A (is)	1999-12-30
AU8362598A (en)	1999-02-08
CN1263533A (zh)	2000-08-16
ATE340801T1 (de)	2006-10-15
EP1000079A1 (en)	2000-05-17
DK1000079T3 (da)	2006-11-20
PT1000079E (pt)	2006-12-29
IL133868A0 (en)	2001-04-30
CY1105805T1 (el)	2011-02-02
TW585764B (en)	2004-05-01
ID24716A (id)	2000-08-03
SA98190328B1 (ar)	2006-08-15
JP4950380B2 (ja)	2012-06-13
HUP0002622A2 (hu)	2001-05-28
MY116421A (en)	2004-01-31
SE9702680D0 (sv)	1997-07-11
NO329918B1 (no)	2011-01-24
ES2273425T3 (es)	2007-05-01
SI1000079T1 (sl)	2007-08-31
EE04119B1 (et)	2003-08-15
NO20000123D0 (no)	2000-01-10
HU226489B1 (en)	2009-03-02

Publication	Publication Date	Title
SK285766B6 (sk)	2007-07-06	Farmaceutická kompozícia obsahujúca nukleotidový analóg a spôsob jej prípravy
US5942510A (en)	1999-08-24	Pharmaceutical composition containing lamotrigine
RU2205012C2 (ru)	2003-05-27	Фармацевтические композиции для сушки вымораживанием
SK280840B6 (sk)	2000-08-14	Lyofilizovaný prípravok obsahujúci 1,1',1''-fosfinotioylidíntrisaziridín a spôsob jeho výroby
AU2003257524B2 (en)	2006-04-06	New formulation
MXPA00000100A (en)	2000-09-08	New formulation
HK1026429B (en)	2007-01-12	New formulation
MXPA99005664A (en)	2000-01-01	Pharmaceutical compositions for freeze drying
HK1026366B (en)	2003-01-10	Pharmaceutical compositions comprising a nucleotide analogue suitable for freeze drying

Legal Events

Date	Code	Title	Description
2018-08-02	MK4A	Patent expired	Expiry date: 20180629